S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
3 Value Stocks Too Small For Buffett’s Portfolio
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:CSTL

Castle Biosciences (CSTL) Stock Price, News & Analysis

$22.15
+0.87 (+4.09%)
(As of 03/28/2024 ET)
Today's Range
$21.33
$22.51
50-Day Range
$18.06
$25.30
52-Week Range
$9.26
$26.70
Volume
380,402 shs
Average Volume
259,251 shs
Market Capitalization
$608.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.00

Castle Biosciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
40.0% Upside
$31.00 Price Target
Short Interest
Bearish
5.17% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.77mentions of Castle Biosciences in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$1.17 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.01) to ($1.78) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.22 out of 5 stars

Medical Sector

555th out of 938 stocks

Medical Laboratories Industry

13th out of 20 stocks

CSTL stock logo

About Castle Biosciences Stock (NASDAQ:CSTL)

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

CSTL Stock Price History

CSTL Stock News Headlines

Grab Your Free Bitcoin Today!
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Grab Your Free Bitcoin Today!
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
CSTL Apr 2024 17.500 call
Castle Biosciences Inc CSTL
Q4 2023 Castle Biosciences Inc Earnings Call
Castle Biosciences Inc (CSTL)
See More Headlines
Receive CSTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Castle Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/28/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:CSTL
Fax
N/A
Employees
610
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.00
High Stock Price Target
$37.00
Low Stock Price Target
$25.00
Potential Upside/Downside
+43.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-57,470,000.00
Pretax Margin
-26.10%

Debt

Sales & Book Value

Annual Sales
$219.79 million
Book Value
$14.54 per share

Miscellaneous

Free Float
25,336,000
Market Cap
$593.47 million
Optionable
Optionable
Beta
0.90
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

CSTL Stock Analysis - Frequently Asked Questions

Should I buy or sell Castle Biosciences stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Castle Biosciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CSTL shares.
View CSTL analyst ratings
or view top-rated stocks.

What is Castle Biosciences' stock price target for 2024?

3 Wall Street analysts have issued 1 year target prices for Castle Biosciences' shares. Their CSTL share price targets range from $25.00 to $37.00. On average, they expect the company's stock price to reach $31.00 in the next twelve months. This suggests a possible upside of 40.0% from the stock's current price.
View analysts price targets for CSTL
or view top-rated stocks among Wall Street analysts.

How have CSTL shares performed in 2024?

Castle Biosciences' stock was trading at $21.58 at the beginning of 2024. Since then, CSTL shares have increased by 2.6% and is now trading at $22.15.
View the best growth stocks for 2024 here
.

Are investors shorting Castle Biosciences?

Castle Biosciences saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 1,420,000 shares, an increase of 17.4% from the February 29th total of 1,210,000 shares. Based on an average daily volume of 252,100 shares, the days-to-cover ratio is currently 5.6 days.
View Castle Biosciences' Short Interest
.

When is Castle Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our CSTL earnings forecast
.

How were Castle Biosciences' earnings last quarter?

Castle Biosciences, Inc. (NASDAQ:CSTL) posted its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.74. The firm had revenue of $66.12 million for the quarter, compared to analysts' expectations of $51.32 million. Castle Biosciences had a negative trailing twelve-month return on equity of 14.92% and a negative net margin of 26.15%.

What ETF holds Castle Biosciences' stock?

First Trust Nasdaq Lux Digital Health Solutions ETF holds 98 shares of CSTL stock, representing 0.21% of its portfolio.

What guidance has Castle Biosciences issued on next quarter's earnings?

Castle Biosciences updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $235.0 million-$240.0 million, compared to the consensus revenue estimate of $214.7 million.

What other stocks do shareholders of Castle Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Castle Biosciences investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), DexCom (DXCM), QUALCOMM (QCOM), Teladoc Health (TDOC), Applied Materials (AMAT), Incyte (INCY) and Intel (INTC).

When did Castle Biosciences IPO?

Castle Biosciences (CSTL) raised $50 million in an initial public offering on Thursday, July 25th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. SVB Leerink and Baird acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Who are Castle Biosciences' major shareholders?

Castle Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Wasatch Advisors LP (9.63%), Granahan Investment Management LLC (8.05%), Principal Financial Group Inc. (5.89%), Vanguard Group Inc. (5.43%), Vanguard Group Inc. (5.32%) and Bellevue Group AG (4.58%). Insiders that own company stock include Adam Jay Sussman, Bernhard E Spiess, Daniel Bradbury, David S Kabakoff, Derek J Maetzold, Derek J Maetzold, Ellen Goldberg, Frank Stokes, Jeffrey E Eberwein, Kristen M Oelschlager, Tiffany Olson and Tobin W Juvenal.
View institutional ownership trends
.

How do I buy shares of Castle Biosciences?

Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CSTL) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners